SC, Cannady DF 2nd, Shuster JJ. Musculoskeletal and prostate effects of combined testosterone and finasteride administration in older hypogonadal men: a randomized, controlled trial. Am J Physiol Endocrinol Metab 306: E433-E442, 2014. First published December 10, 2013; doi:10.1152/ajpendo.00592.2013.-Testosterone acts directly at androgen receptors and also exerts potent actions following 5␣-reduction to dihydrotestosterone (DHT). Finasteride (type II 5␣-reductase inhibitor) lowers DHT and is used to treat benign prostatic hyperplasia. However, it is unknown whether elevated DHT mediates either beneficial musculoskeletal effects or prostate enlargement resulting from higher-than-replacement doses of testosterone. Our purpose was to determine whether administration of testosterone plus finasteride to older hypogonadal men could produce musculoskeletal benefits without prostate enlargement. Sixty men aged Ն60 yr with a serum testosterone concentration of Յ300 ng/dl or bioavailable testosterone Յ70 ng/dl received 52 wk of treatment with testosterone enanthate (TE; 125 mg/wk) vs. vehicle, paired with finasteride (5 mg/day) vs. placebo using a 2 ϫ 2 factorial design. Over the course of 12 mo, TE increased upper and lower body muscle strength by 8 -14% (P ϭ 0.015 to Ͻ0.001), fat-free mass 4.04 kg (P ϭ 0.032), lumbar spine bone mineral density (BMD) 4.19% (P Ͻ 0.001), and total hip BMD 1.96% (P ϭ 0.024) while reducing total body fat Ϫ3.87 kg (P Ͻ 0.001) and trunk fat Ϫ1.88 kg (P ϭ 0.0051). In the first 3 mo, testosterone increased hematocrit 4.13% (P Ͻ 0.001). Coadministration of finasteride did not alter any of these effects. Over 12 mo, testosterone also increased prostate volume 11.4 cm 3 (P ϭ 0.0051), an effect that was completely prevented by finasteride (P ϭ 0.0027). We conclude that a higher-than-replacement TE combined with finasteride significantly increases muscle strength and BMD and reduces body fat without causing prostate enlargement. These results demonstrate that elevated DHT mediates testosterone-induced prostate enlargement but is not required for benefits in musculoskeletal or adipose tissue. testosterone; hypogonadal; prostate enlargement SOME STUDIES OF TESTOSTERONE TREATMENT in older, hypogonadal men report substantial increases in muscle strength and bone mineral density (BMD) (12, 21), whereas others report only modest improvements (31, 41). Studies documenting substantial effects typically employed intramuscular (im) doses of Ն100 mg/wk im injection of long-acting testosterone esters (12, 21). In contrast, lower doses of testosterone that result from transdermal patch or gel administration produce only modest myotrophic effects (31, 32, 41). Meta-analysis data indicate that im testosterone produces a 4% increase in lumbar spine BMD, while transdermal testosterone has no effect (39). Unfortunately, higher doses of testosterone also increase the risk of adverse events, including three that have been confirmed by meta-analysis: polycythemia, a small reduction in HDL-cholesterol, and increased incidence of combined prostate-related events (16, 20, 25) . Currently, many question whether the risk-to-benefit ratio is favorable enough to recommend higher-than-replacement testosterone therapy for the ϳ20% of men aged over 60 yr who are at least moderately hypogonadal (27).
modest improvements (31, 41) . Studies documenting substantial effects typically employed intramuscular (im) doses of Ն100 mg/wk im injection of long-acting testosterone esters (12, 21) . In contrast, lower doses of testosterone that result from transdermal patch or gel administration produce only modest myotrophic effects (31, 32, 41) . Meta-analysis data indicate that im testosterone produces a 4% increase in lumbar spine BMD, while transdermal testosterone has no effect (39) . Unfortunately, higher doses of testosterone also increase the risk of adverse events, including three that have been confirmed by meta-analysis: polycythemia, a small reduction in HDL-cholesterol, and increased incidence of combined prostate-related events (16, 20, 25) . Currently, many question whether the risk-to-benefit ratio is favorable enough to recommend higher-than-replacement testosterone therapy for the ϳ20% of men aged over 60 yr who are at least moderately hypogonadal (27) .
Testosterone exerts direct effects at androgen receptors (ARs) but also undergoes 5␣-reduction to dihydrotestosterone (DHT), which mediates many of the developmental (42) and androgenic effects of testosterone (44) . Both finasteride (type II 5␣-reductase inhibitor) and dutasteride (types I and II 5␣-reductase inhibitor) are used clinically to treat benign prostatic hyperplasia (BPH) and act by significantly reducing endogenous DHT (3) . However, it remains unclear whether elevated DHT mediates the beneficial and/or adverse effects of administered testosterone. A single preliminary report indicates that 200 mg im testosterone enanthate (TE) biweekly plus 5 mg finasteride/day improved total body fat-free mass and lumbar spine and hip BMD and lessened the prostate enlargement resulting from TE alone in older hypogonadal men. However, this combination of TE plus finasteride failed to improve lower-extremity maximal strength over 3 yr (33) . Others have reported that dutasteride (2.5 mg/day) does not limit the dosedependent TE-induced improvements in lean mass or muscle function in younger eugonadal men who were administered a GnRH agonist to suppress endogenous testosterone, although dutasteride did not prevent TE-induced prostate enlargement in this study (11) . As such, questions remain regarding the safety and efficacy of concomitant testosterone and steroid 5␣-reductase inhibitors.
The primary purpose of this study was to determine whether coadministration of higher-than-replacement TE (125 mg/wk) and Proscar (5 mg finasteride/day) increases muscle strength, fat-free mass, and hematocrit in older hypogonadal men while limiting prostate enlargement. Secondary purposes were to determine whether coadministration of higher-than-replacement TE and finasteride improves BMD and body composition without adversely affecting blood lipids.
METHODS

Study Design
This study was approved by the Institutional Review Board of the University of Florida (UF). All participants gave written informed consent. Potential participants underwent screening to determine eligibility, including structured medical history, blood acquisition (performed twice between 8:00 and 10:00 AM, separated by at least 30 min) to determine complete blood count, complete metabolic profile, luteinizing hormone, lipid panel, total and bioavailable testosterone (BioT), hematocrit (Hct), PSA, and a physical exam that included prostate digital rectal examination (DRE) and transrectal ultrasound sizing (TRUS), and American Urological Association International Prostate Symptom Score (AUA/IPSS) (5) . Participants were men aged Ն60 yr, with a serum total testosterone Յ300 ng/dl or BioT Յ70 ng/dl. Two blood samples were obtained during screening, because the Endocrine Society recommends repeated measurements to confirm low testosterone prior to initiating testosterone treatment (9) .
We excluded individuals who failed the Mini-Cog test (13) or who had a history of prostate or breast cancer, severe BPH, AUA/IPPS score Ն25, class 3 or 4 congestive heart failure, sleep apnea, Hct Ͼ49%, PSA Ն2.6 ng/ml, BMI Ͼ35, orthopedic limitations precluding one-repetition maximum (1-RM) strength testing, or who had received testosterone within 4 wk, finasteride/dutasteride within 6 mo, or who were taking Coumadin. Participants were advised to maintain their current level of physical activity.
A randomization table was prepared with RanPro release 1.1 (Applied Logic Associates, Houston, TX) to assign each qualifying participants to one of four treatment groups: vehicle-placebo, TEplacebo, vehicle-finasteride, or TE-finasteride ( Fig. 1 
Protection from Risks
Participants underwent thorough health screenings every 3 mo throughout the study, including all baseline measures described above, with the exception of prostate TRUS (assessed every 6 mo). Participants were removed from the study if the following occurred: hematocrit Ն54%, serum PSA Ն4.0, increase in AUA/IPSS Ն4 points, or if gynecomastia or peripheral edema were noted at physical exam ( Fig. 1) .
Outcomes
Outcome measures were performed at baseline and at 3-mo intervals thereafter except dual X-ray absorptiometry (baseline and 12 mo only) and prostate TRUS (every 6 mo).
Prostate DRE and TRUS. DRE and TRUS were performed by the Urology Service, Malcom Randall VA Medical Center (VAMC), Gainesville, FL. TRUS was performed using the General Electric LOGICQ P5 scanning system with the highest sector transrectal probe/transducer of 7 MHz. The GE LOGICQ has built-in software for electronically calculating prostate volume (height ϫ length ϫ width ϫ 0.52). The same operator performed testing for all participants.
1-RM strength testing. 1-RM strength testing was performed on Cybex (Medway, MA) leg press, knee flexion, knee extension, chest press, and triceps extension selectorized resistance exercise machines. A 5-min warm-up preceded testing, and weights were gradually increased to 1-RM. Testing was repeated within 2-7 days, and the highest load completed was utilized.
Grip strength. Grip strength of the right hand was assessed using a Jaymar hand-held dynamometer (Sammons Preston Roylan, Bolingbrook, IL).
Urinary symptoms. Urinary symptoms were assessed using the AUA/IPPS questionnaire (5). 
Hormone Assays
Body Composition and Lumbar Spine and Hip BMD
These were assessed using a fan-bean densitometer (Lunar Prodigy; GE Medical Systems, Little Chalfont, Buckinghamshire, UK), calibrated daily.
Statistical Methods
Descriptive statistics are given as means with standard deviations (SD) or as means with 95% confidence intervals (CI), as appropriate. P values Ͻ 0.05 (two-sided) were considered statistically significant. Repeated-measures dependent variables were analyzed as linear mixed models with participants as random effects, and time (3, 6, 9, or 12 mo), testosterone, finasteride, interaction, and baseline value of the dependent measures as fixed effects. We utilized an autoregressive correlational structure, allowing measures closer in time to have higher within-subject correlations than when farther apart. Missing at random was presumed for our analyses, and we chose not to use imputation, because it results in greater bias. For variables collected only at baseline and 12 mo, we used a fixed-effects ANOVA model with dependent variable as 12-mo minus baseline difference with the same treatment-related independent variables as above. This coding yields valid interpretable main effects even if interactions are present. The main effect of testosterone, for example, represents the average effect of testosterone under placebo and finasteride (weighted 50 -50). In comparison, the interaction addresses whether or not the difference between the means for treatment factors (e.g., testosterone vs. vehicle) differ quantitatively according to the level of other treatment factors (e.g., finasteride vs. placebo). The changes from baseline to 12 mo are presented, but they estimate a different outcome than the mixed model, which measures an average effect over the times after baseline. The mixed model has two additional advantages over the simple 0-to 12-mo difference comparisons: 1) It uses all of the data, and 2) it is more sensitive than the 0-to 12-mo comparison for effects that increase early and decrease over time.
The study was powered around four end points: fat-free mass, 1-RM leg press, hematocrit, and prostate volume, although a widerange of variables were evaluated due to the systemic nature of androgen-AR interactions and to ensure participant safety. We intended to obtain 12 completers in each of the four arms. Allowing for a 20% dropout rate, the goal was 60 randomized participants. Bhasin et al. (1) reported that older men experience a Ն2 ( ϭ SD) increase in fat-free mass (4.2 Ϯ 0.6 SE, n ϭ 12) and hematocrit (0.07 Ϯ 0.01 SE, n ϭ 12) and 1.18␣ increase in 1-RM strength (28.0 Ϯ 6.8 SE, n ϭ 12) after 20 wk of 125 mg/wk TE, whereas Zitzmann et al. (46) reported that testosterone replacement increased prostate volume 1.85␣ per year (6.1 Ϯ 3.3 SD). For each variable, a 2 ϫ 2 factorial study has 80% power to detect a 0.87 difference at P Ͻ 0.05 (two-sided), and 80% power to detect a 1.0 difference at P ϭ 0.0125 (0.05/4). Importantly, 1-RM strength, fat-free mass, and hematocrit were powered using data from changes occurring over a 20-wk period of testosterone administration, whereas our study duration was 52 wk. As such, we powered to achieve significance in the aforementioned outcomes at the 6-mo time point of our study, which protects against the adverse effects of an unexpectedly high participant dropout rate on statistical power.
RESULTS
Primary Outcomes
Baseline values are reported in Table 1 and treatment effects  in Tables 2-4 and Fig. 2 . TE progressively increased 1-RM strength over 12 mo (Table 2 ) by 12.9 kg for leg press, an 11.4% increase (P Ͻ 0.001; Table 2 and Fig. 2H ), 6.00 kg for knee extension (8.1%, P ϭ 0.012), 5.42 kg for knee flexion (12.5%, P ϭ 0.0023), 6.47 kg for chest press (14.5%, P Ͻ 0.001), 5.32 kg for triceps extension (9.5%, P Ͻ 0.001), and 0.77 kg for grip (11.3%, P ϭ 0.015). TE also increased total body fat-free mass 4.04 kg (P ϭ 0.032; Table 3 and Fig. 2G ) and HCT 4.13% (P Ͻ 0.001; Table 2 (Table 2 ; main effect, P ϭ 0.0051), and finasteride reduced prostate volume by Ϫ5.79cm
3 (main effect, P ϭ 0.0027). These changes resulted in progressive prostate enlargement of 11.4 cm 3 (P ϭ 0.0051) within the TE group, an increase that was fully prevented by finasteride coadministration (P ϭ 0.0027; Fig. 2D ). Prostate volume remained similar between TE-finasteride, vehicle-finasteride, and vehicle-placebo treatments.
Demographic and Blood Values
TE elevated nadir testosterone and BioT, representing 1.8-fold and 2.2-fold increases over baseline, respectively (Table 2 and Fig. 2A ). Finasteride did not affect those increases. TE elevated serum DHT, and finasteride lowered DHT (Table 2 and Fig. 2B ). TE reduced LH to near-zero concentrations, whereas finasteride modestly increased LH (Table 3) . TE elevated E 2 1.7-fold and BioE 2 2.2-fold (P Ͻ 0.001), whereas finasteride had no effect (Table 4) . TE elevated hemoglobin with a time course similar to that of Hct (Table 4) , whereas finasteride had no significant effects on hemoglobin. TE lowered HDL-cholesterol and triglycerides while increasing LDLcholesterol (Table 4) . Finasteride significantly reduced LDLcholesterol while increasing triglycerides (Table 4) . Neither treatment altered total cholesterol. TE significantly decreased CTX-1 but did not affect osteocalcin (Table 4 ). All clinical values remained within normal reference ranges throughout the study (Table 4) .
Body Composition
TE increased lumbar spine BMD 4.19% (P Ͻ 0.001; Table  3 and Fig. 2E ), lumbar spine BMC 3.94% (P ϭ 0.0032), and total hip BMD 1.96% (P ϭ 0.024); BMC was not affected in other regions. TE also reduced total body fat mass 3.87 kg (P Ͻ 0.001; Table 3 and Fig. 2F ), trunk fat 1.88 kg (P ϭ 0.0051; data not shown), and android fat mass 0.42 kg (P Ͻ 0.001; data not shown). Finasteride did not affect the above measurements.
Prostate-Related Measures
TE elevated serum PSA, and finasteride reduced PSA ( Table  2 ). The AUA/IPPS was not altered by treatment. Two participants received prostate biopsies, prompted by DRE findings (one each from the TE-placebo and TE-finasteride groups); both were negative.
DISCUSSION
Testosterone exerts direct effects at ARs and can also induce indirect effects at ARs and/or estrogen receptors (ERs) following the 5␣-reduction to DHT (44) or the aromatization to E 2 (28), respectively. However, the role of DHT in mediating beneficial and/or adverse effects of administered testosterone has received little focus in the literature. We report that 12-mo administration of higher-than-replacement TE (alone) or TE plus finasteride increased fat-free mass, muscle strength, Hct, and lumbar spine and hip BMD while reducing fat mass in older hypogonadal men. TE (alone) also elevated PSA and prostate volume, whereas coadministration of a clinically relevant dose of finasteride completely prevented TE-induced increases in PSA and prostate volume.
In young and older men, testosterone dose-dependently augments lean mass with high-dose TE (600 mg/wk for 10 wk) increasing quadriceps area 7% and muscle strength 10 -12% (10) . In contrast, low-dose testosterone (5 mg/day for 2 yr) increased femoral neck BMD but did not alter muscle strength in older men (31) , suggesting that higher doses of testosterone may be required for improvements in muscle function (41) . In support of this contention, moderate-dose TE (200 mg biweekly) improved lumbar spine and hip BMD, physical performance, and grip strength but did not increase leg strength over 3 yr of treatment (4, 33) . Importantly, equivalent results were observed whether TE was administered alone or in combination with finasteride (14, 23) , indicating that elevated DHT is not required for the beneficial skeletal responses to testosterone in adults. We report similar findings, in that TE plus finasteride markedly reduced DHT while increasing lumbar spine and hip BMD 2-4% (via antiresorptive actions indicated by reduced CTX-1) and total body fat-free mass Ͼ3 kg. Additionally, we observed reductions in total body fat mass of ϳ10% over 12 mo. We expand upon previous findings (33) by demonstrating, for the first time, that coadministration of TE and finasteride improves upper-and lower-body maximal strength in older hypogonadal men. One difference between these studies is that Page et al. (33) measured isokinetic strength, whereas we measured 1-RM strength. Interestingly, type I 5␣-reductase expression appears essential for normal musculoskeletal development, as demonstrated by male 5␣-reductase type I knockout (srd5a1 Ϫ/Ϫ ) mice that exhibit reduced bone mass and muscle force despite normal circulating androgen concentrations (42) . However, 5␣-reductase type I activity is not essential for testosterone-induced myotrophic effects in adult men. As evidence, Bhasin et al. (11) reported that dutasteride did not inhibit TE-induced improvements in lean mass or muscle function in young eugonadal men admin- We also observed that TE treatment significantly elevated serum E 2 and BioE 2 . In this regard, recent evidence indicates that the lipolytic (but not the muscular) effects of testosterone may be influenced by the aromatization of testosterone to E 2 (22) . Additionally, E 2 is a more potent bone antiresorptive agent than testosterone in older men undergoing experimental sex steroid deficiency (at least when administered in doses that result in physiological serum concentrations) (19) . As such, the possibility exists that the lipolytic and bone-protective effects that we observed were, in part, mediated by elevated E 2 . However, this certainly does not preclude the possibility that androgens influence bone and adipose tissue through direct AR-mediated mechanisms. In support of this contention, trenbolone (a highly potent nonaromatizable and non-5␣-reducible testosterone analog) reduces adiposity and preserves bone mass in several animal models of sex steroid deficiency (30, 43) . Additionally, human preadipocytes and mature adipocytes express ARs (35) and nonaromatizable androgens inhibit adipogenesis in human adipose tissue (17) . Human osteoblasts also express ARs at sites of bone formation (1), and physiological testosterone replacement maintains bone formation in older men undergoing experimental sex steroid deficiency (19) . Re- A: significant increase shown in nadir serum testosterone levels following testosteroneenanthate (TE) administration. B: significant increase shown in serum DHT following TE administration and a significant decrease in DHT following finasteride administration. C: significant increase shown in hematocrit following TE administration. D: significant increase shown in prostate volume following TE administration and a significant decrease in prostate volume following finasteride administration. E: significant increase shown in lumbar spine BMD following TE administration. F: significant decrease shown in fat mass following TE administration. G: significant increase shown in fat-free mass following TE administration. H: significant increase shown in 1-RM leg press strength following TE administration. Values are means Ϯ SE; n ϭ 7-13 per group. Effect and interaction columns are derived from repeated-measures analysis for effects of T, F, and Interaction. These effects/interactions are indicative of the mean change occurring over each individual 3-, 6-, 9-, and 12-mo time point, as applicable, with Main Effects representing the average of testosterone under placebo and finasteride (weighted 50 -50) or finasteride under vehicle and testosterone (weighted 50 -50) and Interaction addressing whether or not the difference between the means for the first treatment factor (e.g., testosterone vs. vehicle) differ quantitatively based on the level of the second treatment factor (e.g., finasteride vs. placebo). gardless of the mechanism, the biological significance of our findings is profound given that we have demonstrated that the desirable musculoskeletal and lipolytic effects of higher-thanreplacement testosterone can be obtained without deleterious effects on prostate mass, which significantly improves the safety profile of this clinically relevant treatment. DHT mediates many of the androgenic effects of testosterone, including prostate enlargement, and may worsen prostate cancer risk (29) . Both finasteride and dutasteride are used clinically to treat BPH due to their ability to reduce circulating DHT (38) . However, only two previous clinical studies (4, 11) have examined whether elevated DHT mediates prostate enlargement following testosterone administration, with somewhat conflicting results. Bhasin et al. (11) reported that graded doses of TE (ranging from 50 to 600 mg/wk) increased prostate volume ϳ2.5cm 3 over 20 wk in young men and that dutasteride did not prevent this enlargement. Conversely, Amory et al. (4) reported that TE (200 mg biweekly) increased prostate volume 14 cm 3 over 3 yr in older hypogonadal men and that finasteride coadministration limited prostate enlargement to only 5 cm 3 . Others reported that men receiving testosterone by patch, gel, or injection experienced prostate volume increases of 4.9 cm 3 /yr of treatment (46) and that coadministration of transdermal testosterone (1% T gel) and dutasteride reduced prostate size in older men with BPH (34) . Similarly, we report that the main effect of 125 mg/wk TE on prostate volume was 5.3 cm 3 when administered to hypogonadal older men; however, this underestimates the actual 12-mo change in the TE-placebo group (11.4 cm 3 ), because finasteride coadministration completely prevented TE-induced prostate enlargement.
E438 TESTOSTERONE AND FINASTERIDE IN OLDER MEN
AJP-Endocrinol Metab
Testosterone dose-dependently increases hemoglobin and hematocrit, possibly independently of erythropoietin, and this effect is greater in older men compared with younger (18) . We observed a 4 -5 point Hct increase following administration of either TE or TE plus finasteride; suggesting that elevated DHT does not mediate this change. The Hct increase that occurs in most older men receiving testosterone is not considered detrimental and may be beneficial (37) , although this must be weighed against the risk of polycythemia (25) and associated cardiovascular risks (23) .
Several meta-analyses (16, 25) have identified polycythemia, combined incidence of prostate events (including elevated PSA, increased urinary symptoms, number of prostate biopsies, and prostate cancer), and a modest reduction in HDLcholesterol as the three proven adverse events resulting from testosterone administration. Rates of adverse events were similar between groups in our study, although we observed that TE lowered HDL by ϳ10%, an effect not altered by finasteride. TE also increased LDL 29% and reduced triglycerides. Conversely, finasteride coadministration reduced LDL-cholesterol but did not alter triglycerides. The clinical ramifications of these blood lipid changes remains unknown (36) . Additionally, several putative adverse events are associated with testosterone administration, including worsening of sleep apnea, edema, gynecomastia, increased incidence of cardiovascular events, acceleration of underlying prostate cancer, and liver-related side effects (6, 7, 25) . In this regard, coadministration of testosterone plus finasteride has some advantages, including lessening of androgen-induced prostate enlargement, and some potential disadvantages compared with treatment with testosterone alone, including altering the clinical usefulness of PSA measurements (29) . However, the value of PSA testing has come into question, especially in men aged Ն70 yr (8) . Testosterone administration combined with 5␣-reductase inhibition may also alter prostate cancer risk or severity, given that finasteride alone reduces the incidence of prostate cancer while increasing the number of prostate cancers with Gleason scores of 7-10 (38) . Similarly, testosterone-stimulated prostate cancer growth in culture is ablated by dutasteride (2), perhaps through mechanisms involving upregulation of testosterone-sensitive tumor suppressors (24). [11] As with all studies, several limitations exist with our data set, including a relatively small sample size and a slightly higher than expected non-completion rate. In this regard, the 2 ϫ 2 factorial design that we utilized is the most powerful study design to detect outcomes resulting from a combination pharmacological therapy and allows for adequate power with smaller sample sizes. To ensure an appropriate sample size, we powered to detect differences in three of four primary outcomes (i.e., 1-RM strength, fat-free mass, and Hct) at the 6-mo time point despite the 12-mo duration of our study. In this regard, we met our expected non-completion rate of 20% at 6 mo, whereas the 12-mo noncompletion rate in our study (i.e., 33%) was slightly higher than anticipated. Importantly, noncompletion was similar among all groups ( 2 P value ϭ 0.48, indicating no differences) and was comparable to the noncompletion rates of 27-29% in other long-term testosterone studies (4, 11, 26) . Additionally, our non-completion rate was not exceedingly high, given that once-weekly visits to the hospital were required for 52 consecutive weeks and that we observed a significant main effect for testosterone in each of our primary and secondary outcomes and a significant interaction for prostate volume (the only primary outcome powered on 12-mo data), as hypothesized. Indeed, we detected all a priori hypotheses for primary and secondary outcomes. However, it remains theoretically possible that we did not observe significant interactions (at the 12-mo time point) because our noncompletion rate resulted in a slightly lower than expected power to detect such outcomes. We believe this to be highly unlikely given that the 0-to 12-mo changes and point estimates (i.e., 95% CI) for the vast majority of our data were directionally similar and of a comparable magnitude in the 1) testosterone-placebo and testosterone-finasteride groups and 2) vehicle-placebo and vehicle-finasteride groups. Regardless, when one is interpreting our data, nonsignificant interactions should not be used to infer that an interaction was not present. In addition to the above mentioned limitations, some nonsignificant differences also existed between groups at baseline. To account for this random variability, baseline values were included in our statistical model as fixed effects. Additionally we examined the baseline characteristics of the randomized cohort (n ϭ 60) and of the completers (n ϭ 40) and observed no differences between cohorts, indicating that completers were representative of the overall randomized cohort. Irrespective of these limitations, we report significance in each of our primary and secondary outcomes, demonstrating the robustness of our data and that our study achieved appropriate power to detect all desired outcomes.
In conclusion, our results add to the growing number of preclinical (24 -26) and clinical trials (4, 11, 33) reporting that musculoskeletal and lipolytic improvement can be obtained [11] without prostate enlargement when higher-than-replacement testosterone is coadministered with finasteride (an inhibitor of the type II 5␣-reductase enzyme). These findings indicate that elevated DHT is not required for the benefits of exogenous testosterone and support the contention that finasteride ablates prostate enlargement associated with higher-than-replacement TE administration. As such, our findings provide a rationale for larger and more comprehensive clinical trials examining the safety and efficacy of higher-than-replacement testosterone plus finasteride/dutasteride treatment in hypogonadal elderly men.
